CST, 93334S, TMEM106B (E7H7Z) Rabbit Monoclonal Antibody

Monoclonal Antibody for studying TMEM106B. Validated for WB,IP,IHC,IF,IF. Available in 2 sizes. Highly specific and rigorously validated in-house, TMEM106B (E7H7Z) Rabbit Monoclonal Antibody (CST #93334) is ready to ship. Product Usage Information Western Blotting: 1:1000 Immunoprecipitation: 1:50 Immunohistochemistry (Paraffin): 1:50 Immunofluorescence (Frozen): 1:100 Immunofluorescence (Immunocytochemistry): 1:50 - 1:200 Storage Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at -20°C. Do not aliquot the antibody. Protocol Available protocols: Western Blotting, Immunoprecipitation, Immunohistochemistry (Paraffin), Immunofluorescence (Frozen), Immunofluorescence (Immunocytochemistry) Specificity / Sensitivity TMEM106B (E7H7Z) Rabbit Monoclonal Antibody recognizes endogenous levels of total TMEM106B protein. 93334 shows questionable staining in few tissues, including staining of a subset of cells among normal colon epithelium, squamous epithelium staining of one salivary tumor, and staining of cytoplasmic spots in one lymphoma. Species Reactivity: Human, Mouse, Rat Source / Purification Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Ala17 of human TMEM106B protein. Background Transmembrane protein 106B (TMEM106B) is a type II transmembrane protein with unknown function (1). was first identified as a major risk factor in genome-wide association studies in patients with frontotemporal lobar degeneration (FTLD), a neurodegenerative disorder characterized by atrophy in the frontal and temporal lobes of the brain (2). Localization of TMEM106B in late endosomal/lysosomal compartments suggests a role in regulating endo-lysosomal morphology and function (3). Endo-lysosomal dysfunction is likely a major cellular pathway that contributes to FTLD as other genetically linked FTLD genes, including , , and , converge on this cellular pathway (4). TMEM106B is sequentially processed through ectodomain shedding, followed by intramembrane proteolysis, with possible variability in the intramembrane cleavage site. Fragments consisting of residues 120-254 of TMEM106B have been shown to form amyloid filaments in human brains (5-7). Alternate Names FLJ11273; HLD16; MGC33727; T106B; TMEM106B; TMEM106B protein; Transmembrane protein 106B Specification REACTIVITY: H M R SENSITIVITY: Endogenous MW (kDa): 42 Source/Isotype: Rabbit IgG